The incidence and cost of hospitalization for 5-FU toxicity among medicare beneficiaries with metastatic colorectal cancer

Value in Health

Volumn 5, Issue 1, 2002, Pages 35-43

  Delea, T E ^a   Vera Llonch, M ^a   Edelsberg, J S ^a   McGarry, L ^b   Anton, S ^c   Ulcickas Yood, M ^d   Oster, G ^a  

^a POLICY ANALYSIS INC PAI   (United States)

^b i3 Global   (Canada)

^c BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^d BRISTOL MYERS SQUIBB   (United States)

Author keywords

5 fluorouracil; Colorectal cancer; Cost analysis; Costs; Toxicity

Indexed keywords

FLUOROURACIL;

AGED; AGRANULOCYTOSIS; ARTICLE; COLORECTAL CANCER; COLORECTAL SURGERY; CONTROLLED STUDY; COST OF ILLNESS; FEMALE; GASTROENTERITIS; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICARE; NAUSEA; PRIORITY JOURNAL; STOMATITIS; VOMITING;

EID: 0036168464     PISSN: 10983015     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1524-4733.2002.51083.x     Document Type: Article

References (46)

1. Colorectal cancer
2. Biochemical modulation of fluorouracil with leucovorin: Confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer
3. Biochemical modulation of fluorouracil: Evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma
4. A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma
5. Superiority of sequential methotrexate, fluorouracil and leucovorin to fluorouracil alone in advanced symptomatic colorectal carcinoma: A randomized trial
6. Prospective randomized trial of 5-fluorouracil versus 5-fluorouracil plus levamisole in the treatment of metastatic colorectal cancer: A Hoosier Oncology Group Trial
7. Chemotherapy for colorectal cancer
8. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer
9. A prospective randomized study comparing high- and low-dose leucovorin combined with same-dose 5-fluorouracil in advanced colorectal cancer
10. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: A French Intergroup Study
11. Prospectively randomized North Central Cancer Treatment Group Trial of intensive-course fluorouracil combined with the 1-isomer of intravenous leucovorin, oral leucovorin, or intravenous leucovorin for the treatment of advanced colorectal cancer
12. A prospective randomized trial of protracted venous infusion 5-fluorouracil with or without mitomycin C in advanced colorectal cancer
13. Fluorouracil plus racemic leucovorin versus fluorouracil combined with the pure 1-isomer of leucovorin for the treatment of advanced colorectal cancer: A randomized phase III study
14. Fluorouracil and leucovorin with or without interferon alfa-2b in advanced colorectal cancer: Analysis of a prospective randomized phase III trial
15. Folinic acid does improve 5-fluorouracil activity in vivo. Results of a phase III study comparing 5-fluorouracil to 5-fluorouracil and folinic acid in advanced colon cancer patients
16. Weekly regimen of 5-FU + intermediate dose folinic acid in the treatment of advanced colorectal cancer
17. Prospective randomized comparison of fluorouracil versus fluorouracil and high-dose continuous infusion leucovorin calcium for the treatment of advanced measurable colorectal cancer in patients with previously unexposed to chemotherapy
18. Randomized study of continuous infusion fluorouracil versus fluorouracil plus cisplatin in patients with metastatic colorectal cancer
19. The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma a prospective randomized phase III trial
20. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: A mid-Atlantic oncology program study
21. The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: A prospective randomized phase III trial
22. Treatment of patients with advanced colorectal carcinomas with fluorouracil alone, high-dose leucovorin plus fluorouracil, or sequential methotrexate, fluorouracil and leucovorin: A randomized trial of the Northern California Oncology Group
23. Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: Results of a randomized trial in patients with advanced colorectal cancer
24. A prospective randomized trial of fluorouracil versus fluorouracil plus cisplatin in the treatment of metastatic colorectal cancer: A Hoosier Oncology Group trial
25. 5-Fluorouracil and folinic acid in the treatment of metastatic colorectal cancer: A randomized comparison
26. A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma
27. Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer
28. Age and sex are independent predictor of 5-fluorouracil toxicity. Analysis of a large-scale phase III trial
29. The National Cancer Data Base report on colon cancer
30. A national population-based study of incidence of colorectal cancer and age. Implications for screening older Americans
31. Racial disparity in the incidence and case-fatality of colorectal cancer: Analysis of 329 United States counties
32. Surgery for colorectal cancer: Race-related differences in rates and survival among Medicare beneficiaries
33. Ability of Medicare claims data and cancer registries to identify cancer cases and treatment
34. Measuring the incidence of cancer in elderly Americans using Medicare claims data
35. Potential for cancer-related health services research using a linked Medicare-tumor registry database
36. Nonparametric estimation from incomplete observations
37. Statistical aspects of the analysis of data from retrospective studies of disease
38. Regression models and life-tables (with discussion)
39. Estimating medical costs from incomplete follow-up data
40. Colorectal cancer-an undertreated disease
41. Accuracy of Medicare claims data for estimation of cancer incidence and resection rates among elderly Americans
42. Use of Medicare claims data to measure county-level variations in the incidence of colorectal carcinoma